- Aktuelle Seite:
-
Home
-
Wirtschaft
- Legal
Indivior (US): Our Commitment - Updates on the Department of Justice’s Action
We are extremely disappointed in this action by the Justice Department, which is wholly unsupported by either the facts or the law. Key allegations made by the Justice Department are contradicted by the government’s own scientific agencies, they are almost exclusively based on years-old events from before Indivior became an independent company in 2014, and they are wrong. As we fight these allegations aggressively, we are committed to remaining focused on our mission of helping patients and communities struggling with opioid addiction. (indivior.com, Stand 05.09.2019)
http://indivior.com/commitment/
USA. Sacklers vs. States: Settlement Talks Stumble Over Foreign Business
The Sackler family is willing to give up Purdue Pharma to settle all claims related to the opioid crisis, but is resisting a quick sale of its overseas drug company.(...) The Sacklers are deep in negotiations that, if finalized, would force them to give up ownership of Purdue, the company widely blamed for the onset of the opioid epidemic with its aggressive marketing of the prescription painkiller OxyContin. But they want to keep selling OxyContin and other drugs abroad for as many as seven more years, through another company they own, Mundipharma, based in Cambridge, England. (New York Times, 30.08.2019)
https://www.nytimes.com/2019/08/30/health/purdue-sacklers-opioids-settlement.html
Philip Morris International: money over morality?
The Lancet, Volume 394, Issue 10200, 709
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31998-1/fulltext
Philip Morris and Altria Are in Talks to Merge
With Altria’s investment in Juul, a combination of the tobacco giants would dominate the international market for e-cigarettes. (New York Times, 27.08.2019)
https://www.nytimes.com/2019/08/27/health/philip-morris-altria-merger-tobacco.html
Indien. Beset By Lawsuits And Criticism In U.S., Opioid Makers Eye New Market In India
What began in India as a populist movement to bring inexpensive morphine to the diseased and dying poor has paved the way for a booming pain management industry. Now, new customers are being funneled to U.S. drugmakers bedeviled by a government crackdown back home. (KHN – Kaiser Health News, USA, 28.08.2019)
https://khn.org/news/india-burgeoning-chronic-pain-market-us-drugmakers-stand-to-profit
USA. Sacklers Would Give Up Ownership of Purdue Pharma Under Settlement Proposal
The Sackler family would give up ownership of Purdue Pharma, the company blamed for much of the opioid epidemic, and pay $3 billion of their own money under terms of a settlement proposal to resolve thousands of federal and state lawsuits, according to a person familiar with the negotiations. (New York Times, 27.08.2019)
https://www.nytimes.com/2019/08/27/health/sacklers-purdue-pharma-opioid-settlement.html
USA. Johnson & Johnson Ordered to Pay $572 Million in Landmark Opioid Trial
Oklahoma pursued the first case against a drug manufacturer for the national public health disaster, and the ruling may point to what lies ahead in 2,000 more lawsuits. (New York Times, 26.08.2019)
https://www.nytimes.com/2019/08/26/health/oklahoma-opioids-johnson-and-johnson.html
USA. Purdue Pharma offers $10-12 billion to settle opioid claims
The lawsuits allege the company and the Sackler family are responsible for starting and sustaining the opioid crisis. (NBC News, USA, 28.08.2019)
USA. Drug makers conspired to worsen the opioid crisis. They have blood on their hands
Johnson & Johnson and others profited from addiction and death – and yet they still don’t think they’ve done anything wrong. (The Guardian, UK, 29.08.2019)
https://www.theguardian.com/commentisfree/2019/aug/29/opioids-crisis-drug-makers-pharma
US opioid prescribing: the federal government advisers with recent ties to big pharma
BMJ2019;366, doi.org/10.1136/bmj.l5167
https://www.bmj.com/content/366/bmj.l5167
The Big Pharma Takeover of Medical Cannabis
As evidence of cannabis’ many benefits mounts, so does the interest from the global pharmaceutical industry, known as Big Pharma. The entrance of such behemoths will radically transform the cannabis industry—once heavily stigmatized, it is now a potentially game-changing source of growth for countless companies.
Today’s infographic comes to us from CB2 Insights, and explores how and why the notorious Big Pharma are interested in the nascent cannabis industry. (Visual Capitalist, USA, 12.08.2019
https://www.visualcapitalist.com/the-big-pharma-takeover-of-medical-cannabis
Fair(er) Trade Options for the Cannabis Market
Martin Jelsma, Sylvia Kayand David Bewley-Taylor
TNI – Trans National Institute, Policy Report 1, March 2019
(...) Many for-profit cannabis companies from the Global North are aggressively competing to capture the licit spaces now rapidly opening in the multi-billion-dollar global cannabis market. This threatens to push small-scale and marginalized traditional farmers from many countries in the Global South out of the emerging legal market. (TNI, Niederlande, 02.03.2019)
https://www.tni.org/en/publication/fairer-trade-options-for-the-cannabis-market
USA. Capitalism gone wrong: how big pharma created America's opioid carnage
A web of firms ramped up narcotic painkiller sales, creating the biggest drug epidemic in American history as profits surged. (The Guardian, UK, 24.07.2019)
https://www.theguardian.com/us-news/2019/jul/24/opioids-crisis-big-pharma-drugs-carnage
USA. In den USA erzielt ein Vergleich über Opioid-Vermarktung einen neuen Rekord
Der britische Konzern Reckitt Benckiser lässt die Abwehr einer Strafklage 1,4 Milliarden Dollar kosten. Es geht um das Medikament Suboxone, das zur Suchtbehandlung angeboten wurde. Die Anklage fordert in einem weiteren Fall zum gleichen Medikament mindestens drei Milliarden Strafe. (Neue Zürcher Zeitung, 12.07.2019)
USA. Reckitt Benckiser zahlt Milliardenstrafe in den USA
London – Reckitt Benckiser legt den Streit mit den US-Behörden wegen verbotener Marketingmethoden für sein Kombinationspräparat Suboxone Film mit einer Milliardenzahlung bei. (aerzteblatt.de, 11.07.2019)
https://www.aerzteblatt.de/nachrichten/104566/Reckitt-Benckiser-zahlt-Milliardenstrafe-in-den-USA
USA. Marketing förderte Verordnung von Gabapentin und Biologika in den USA
Farmington/Connecticut und Toronto – Ärzte, die von Pharmafirmen zum Essen oder auf kostenlose Fortbildungsveranstaltungen eingeladen oder für Beratertätigkeiten sowie Vorträge honoriert werden, verordnen in der Folge häufiger die Medikamente der Hersteller. (aerzteblatt.de, 10.07.2019)
USA. Study: More Pharma Money, More Gabapentin
Payments to doctors by pharmaceutical companies may be influencing them to prescribe more expensive, brand-name versions of the pain drug gabapentin, a team of researchers report in the July 8 issue of JAMA Internal Medicine,and the increasing use of the drug suggests it may be being abused. (University of Connectecut, USA, 08.07.2019)
https://today.uconn.edu/2019/07/study-more-pharma-money-more-gabapentin/
US teens may be finding it harder to buy cannabis after legalisation
Does legalising cannabis make it easier for teenagers to access the drug? The largest study to date suggests not – and it may even have the opposite effect.
In US states that have legalised recreational use of marijuana, fewer teenagers reported taking the drug after the laws were passed. (New Scientist, UK, 08.07.2019)
The Philip Morris-funded Foundation for a Smoke-Free World: tax return sheds light on funding activities
Legg, Tess et al.
The Lancet, Volume 393, Issue 10190, 2487 - 2488
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31347-9/fulltext
CompWareMedical. Datendiebe im Unternehmen: Wie ein Hidden Champion einen internen Spion enttarnte
Die meisten Angriffe auf Unternehmensdaten kommen von außen? Gerd Meyer-Philippi, Geschäftsführer des Medizintechnikherstellers Compware Medical, hat das Gegenteil erlebt. Seine Spione arbeiteten im eigenen Unternehmen. (Markt und Mittelstand, 06.06.2019)
USA. Opioidhersteller in den USA zahlt Millionenstrafe
New York – Inmitten der Opioidkrise in den USA hat sich ein Schmerzmittelhersteller wegen Schmiergeldzahlungen an Ärzte zur Zahlung einer Millionenstrafe bereiterklärt. Insys Therapeutics zahle in den nächsten fünf Jahren 225 Millionen Dollar (200 Millionen Euro), dafür würden alle Ermittlungen der Regierung zum Vertrieb des Fentanyl-Sprays Subsys eingestellt, teilte das US-Justizministerium gestern mit. (aerzteblatt.de, 06.06.2019)
https://www.aerzteblatt.de/nachrichten/103665/Opioidhersteller-in-den-USA-zahlt-Millionenstrafe
USA. Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global Resolution of Criminal and Civil Investigations
Company Admits Illegal Conduct Regarding Promotion of Subsys, a Powerful Opioid Painkiller. (US Government, Department of Justice, 05.06.2019)
USA. California joins opioid fight, sues Purdue Pharma over marketing of OxyContin
California on Monday sued Purdue Pharma over its marketing and sale of the drug OxyContin, alleging it is contributing to the nationwide opioid crisis that has caused thousands of overdose deaths in the state. (Los Angeles Times, USA, 03.06.2019)
https://www.latimes.com/politics/la-pol-ca-oxycontin-maker-sued-by-california-20190603-story.html
USA. Opioid-Krise in Amerika : Wenn Ärzte süchtig machen
Jeden Tag sterben in den Vereinigten Staaten 115 Menschen an einer Überdosis opioidhaltiger Mittel. Für viele Opfer bahnte das Schmerzmittel Oxycontin der Pharmafirma Purdue den Weg in die Abhängigkeit. Die Vereinigten Staaten erleben eine Gesundheitskrise, die mehr Opfer fordert als die Kriege in Vietnam und im Irak. (Frankfurter Allgemeine, 08.05.2019)
USA. More states sue opioid maker alleging deceptive marketing
California, Hawaii, Maine and the District of Columbia filed lawsuits Monday against the maker of OxyContin and the company's former president, alleging the firm falsely promoted the drug by downplaying the risk of addiction while it emerged as one of the most widely abused opioids in the U.S.(MedicalXpress, USA, 04.06.2019)
https://medicalxpress.com/news/2019-06-states-sue-opioid-maker-alleging.html
USA. Opioid Lawsuits Push American Pain Society to Brink of Bankruptcy
Alicia Ault.
Medscape - May 29, 2019.
https://www.medscape.com/viewarticle/913634
USA. White Collar Watch: RICO Offers a Powerful Tool to Punish Executives for the Opioid Crisis
The conviction of John Kapoor, the Insys Therapeutics founder, and four other executives at the pharmaceutical firm on racketeering charges this month was a significant step toward imposing substantial penalties on corporate officials for contributing to the nation’s opioid epidemic. (New York Times, 23.05.2019)
https://www.nytimes.com/2019/05/23/business/dealbook/rico-insys-opioid-executives.html
HIV-Arzneimittelkosten sinken trotz steigender Patientenzahlen
Waldems-Esch – Die Zahl deutscher HIV-Infizierter steigt seit Jahren an und liegt derzeit bei mehr als 85.000 Betroffenen. Hintergrund ist die hohe Lebenserwartung der Patienten unter Therapie. Trotzdem sind die Arzneimittelabsätze im HIV-Markt und die Ausgaben rückläufig, wie neue Zahlen zeigen. (aerzteblatt.de, 30.05.2019)
USA. Auslöser der US-Suchtkrise?- Prozessauftakt gegen Pharma-Riesen Johnson & Johnson
Das Pharma-Unternehmen Johnson & Johnson steht vor Gericht. Geklagt hat der US-Bundesstaat Oklahoma.
Es geht um die Opiat-Sucht in den USA, die immer wieder Todesopfer fordert.
Der Schmerzmittelhersteller wird in der Klage mitverantwortlich gemacht für diese Suchtkrise.
Der Prozess gilt als richtungsweisend, denn 1600 Gemeinden und 40 Gliedstaaten haben gegen Unternehmen, die Opioid-Schmerzmittel produzieren, ebenfalls Klagen eingereicht.
(SRF, Schweiz, 28.05.2019)
USA. Opioid-Krise: Ratiopharm-Mutter Teva zahlt 85 Millionen US-Dollar
In den USA geht die Strafverfolgung der mutmaßlichen Verantwortlichen an der Opioid-Krise weiter. Im US-Bundesstaat Oklahoma sollten am heutigen Dienstag die Prozesse gegen den israelischen Generika-Riesen Teva und Johnson & Johnson (J&J) beginnen. Während sich J&J für ein Gerichtsverfahren „bereit“ fühlt, hatte die Ratiopharm-Mutter hatte am vergangenen Sonntag einer Vergleichszahlung von 85 Millionen US-zugestimmt – allerdings ohne dabei ein Fehlverhalten zuzugeben. (DAZ – Deutsche Apotheker Zeitung, 28.05.2019)
Seite 1 von 13